Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases acid production in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. A lower dose of 20 mg orally once daily may be used in some patients.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is 40 mg orally or intravenously twice daily. Doses can be increased to 240 mg intravenously or 100 mg orally once daily. Doses greater than 40 mg twice daily should be administered via IV infusion.
## Pediatric Dosing
* **GERD-associated erosive esophagitis (5 to 16 years):** 20 mg orally once daily for up to 8 weeks.
* **GERD-associated erosive esophagitis (greater than or equal to 17 years):** Same as adult dosing.
* *Note:* Intravenous formulations are not approved for pediatric use. Use in younger children is off-label and requires careful consideration.
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic impairment, although maximum daily doses should not exceed 40 mg orally or 20 mg intravenously. No dose adjustment is typically needed for patients with renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the efficacy of clopidogrel.
* **Methotrexate:** Concurrent use may increase methotrexate levels, potentially leading to toxicity.
* **Drugs requiring gastric acid for absorption (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors):** Pantoprazole can decrease absorption.
* **CYP2C19 and CYP3A4 substrates:** Pantoprazole may affect the metabolism of these drugs.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, muscle cramps, seizures).
* Monitor for signs of *Clostridium difficile*-associated diarrhea.
* Consider vitamin B12 levels with long-term therapy.
## Clinical Pearls
* Oral pantoprazole is generally preferred over IV for patients who can tolerate oral medications.
* IV pantoprazole should be administered as an infusion, not as a bolus injection.
* PPIs are most effective when taken 30-60 minutes before a meal.
* Discontinuation of PPIs should be gradual to avoid rebound acid hypersecretion.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local institutional protocols for definitive guidance.*
